Latest News and Press Releases

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – August 27, 2025Idorsia Ltd (SIX: IDIA) settled the repurchase offer for its outstanding CHF 204* million convertible bonds maturing...

The updated recommendations now include TRYVIO™ (aprocitentan) – the first and only hypertension treatment targeting the endothelin pathway.Endothelin is upregulated in hypertension and is a...

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – August 19, 2025Idorsia Ltd (SIX: IDIA) announces the end results of the repurchase offer for its outstanding CHF 204* million...

Allschwil, Switzerland – August 12, 2025Idorsia Ltd (SIX: IDIA) announced today that The Galien Foundation, the premier global institution dedicated to honoring innovators in life sciences, has...

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – August 11, 2025Idorsia Ltd (SIX: IDIA) announces the interim results of the repurchase offer for its outstanding CHF 204* million...

Ad hoc announcement pursuant to Art. 53 LR QUVIVIQ™ (daridorexant): Strong performance and sales acceleration with total net sales of CHF 58 million in H1 2025 and increase of 145% compared to the...

Ad hoc announcement pursuant to Art. 53 LR Potential first-ever vaccine directed against C. difficile bacteria and spores induces positive antigen titers in humans that recognize the bacteriaInitial...

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – June 25, 2025Idorsia Ltd. (SIX: IDIA) today announced the positive outcome of two bondholder meetings held at 17:30 CEST and 19:00...

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – June 25, 2025Idorsia Ltd (SIX: IDIA) today announced the launch of the repurchase offer to the holders of its outstanding CHF 200...

Ad hoc announcement pursuant to Art. 53 LR Idorsia to receive USD 50 million (an additional USD 30 million) approval milestone payment in return for a reduction in Simcere potential sales milestones...